Hepatitis C can be transmitted through blood transfusions, organ transplants, percutaneous (especially IV drug use), sexual or perinatal route.
It has an incubation period of 14-180 days.
Goal of treatment is to prevent progression to chronic hepatitis C through antiviral treatment of acute hepatitis C. Also, it aims to prevent occurrence of liver-related complications through antiviral treatment of chronic hepatitis C.
Reducing the wait time for the hepatitis C virus (HCV) rapid antibody point-of-care test, from 20 minutes to 5 minutes, does not affect its sensitivity and is just as good for ruling out infection, according to a study.
Achieving the World Health Organization’s (WHO) target to eliminate hepatitis C virus (HCV) by 2030 is possible in Singapore, but this requires immediate scaling up of treatment among injectable drug users (IDUs) together with harm reduction efforts, as suggested in a study.
Use of direct-acting antivirals to treat hepatitis C virus (HCV) in hepatocellular carcinoma (HCC) patients with documented response to therapy appears to yield a significant reduction in mortality, as shown in a recent study.
Diabetic patients with hepatitis C virus (HCV) may benefit from direct-acting antiviral agents, with a significant portion of patients having a clinically significant reduction in glycated haemoglobin (HbA1c), suggests a recent study. This effect has been sustained among responders over 1.5 years of follow-up.
Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress™ (ILC 2019) showed.
The use of glecaprevir plus pibrentasvir appears to be safe and highly effective in the treatment of chronic hepatitis C virus (HCV) infection genotypes 1–3 in patients with severe renal impairment, including those undergoing haemodialysis, as shown in a recent study from Japan.
Combination treatment with glecaprevir plus pibrentasvirproduces a sustained virological response in more than 90 percent of hepatitis C virus (HCV)-infected patients who previously failed direct-acting antiviral (DAA) treatments, regardless of liver fibrosis stage, a study has shown.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.